Preclinical studies showed that treatment with ivosidenib decreased intracellular 2-HG levels in IDH1-mutant AML cells in vitro [7], and resulted in 2-HG inhibition in tumors in an IDH1-mutant xenograft mouse model [6]. This evidence concerns the gene IDH1 and acute myeloid leukemia.